Literature DB >> 12861399

Loss of expression of DNA repair enzymes MGMT, hMLH1, and hMSH2 during tumor progression in gastric cancer.

Yoshihiko Kitajima1, Kohji Miyazaki, Shiroh Matsukura, Masayuki Tanaka, Mutsuo Sekiguchi.   

Abstract

BACKGROUND: Disorders of the DNA repair system that protects against alkylating mutagens are known to play an important role in carcinogenesis.
METHODS: We investigated the expression of the DNA repair enzyme that protects against alkylating mutagens, O(6)-methylguanine DNA methyltransferase (MGMT), and the mismatch repair (MMR) enzymes, hMLH1 and hMSH2, in 135 gastric cancer specimens by immunohistochemical means.
RESULTS: The immunoreactivity of MGMT and MMR proteins correlated significantly with several clinicopathologic factors. The survival curve in 116 patients showed that a loss of MGMT or hMLH1, but not of hMSH2, correlated with a poor prognosis. Combined evaluation of MGMT and hMLH1 revealed that the survival of patients with negative status for both MGMT and hMLH1 was shortest. However, this significant association between patient survival and MGMT or hMLH1 expression disappeared when early and advanced cancers were separately analyzed, indicating that synchronous losses of MGMT and hMLH1 increase during tumor progression and stage. Further evaluation according to histologic type revealed that loss of MGMT, hMLH1, and hMSH2 expression significantly differed between early and advanced cancer in differentiated-type cancers. In contrast, in undifferentiated-type cancer, loss of MGMT and MMR expression was frequently found even in intramucosal (m) cancer, and no significant difference was found in loss of hMLH1 and hMSH2 between early and advanced cancer.
CONCLUSION: These findings demonstrate that the reduced expression of MGMT, hMLH1, and hMSH2 in differentiated-type cancer may play an important role during tumor progression between the early and advanced stage. On the other hand, in undifferentiated-type cancer, loss of MGMT and the MMR proteins appears to be an important event at carcinogenesis or at an earlier step of tumor progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12861399     DOI: 10.1007/s10120-003-0213-z

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  11 in total

1.  Role of loss of o⁶-methylguanine dna methyltransferase (MGMT) expression in non-small cell lung carcinomas (NSCLCs): with reference to the relationship with p53 overexpression.

Authors:  Na-Hye Myong
Journal:  Cancer Res Treat       Date:  2010-06-30       Impact factor: 4.679

2.  Epigenetic reduction of DNA repair in progression to gastrointestinal cancer.

Authors:  Carol Bernstein; Harris Bernstein
Journal:  World J Gastrointest Oncol       Date:  2015-05-15

3.  MGMT and MLH1 methylation in Helicobacter pylori-infected children and adults.

Authors:  Marisa C Alvarez; Juliana C Santos; Nathália Maniezzo; Marcelo S Ladeira; Artur L C da Silva; Isabel C A Scaletsky; José Pedrazzoli; Marcelo L Ribeiro
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

4.  Influence of Helicobacter pylori infection on the expression of MLH1 and MGMT in patients with chronic gastritis and gastric cancer.

Authors:  W Bartchewsky; M R Martini; A C Squassoni; M C Alvarez; M S P Ladeira; D M F Salvatore; M A Trevisan; J Pedrazzoli; M L Ribeiro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-12-17       Impact factor: 3.267

5.  Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients.

Authors:  Mayumi Mitsuno; Yoshihiko Kitajima; Takao Ide; Kazuma Ohtaka; Masayuki Tanaka; Seiji Satoh; Kohji Miyazaki
Journal:  J Gastroenterol       Date:  2007-11-22       Impact factor: 7.527

6.  Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus.

Authors:  Doerthe Kuester; Wa'el El-Rifai; DunFa Peng; Petra Ruemmele; Ivonne Kroeckel; Brigitte Peters; Christopher A Moskaluk; Manfred Stolte; Klaus Mönkemüller; Frank Meyer; Hans-Ulrich Schulz; Arndt Hartmann; Albert Roessner; Regine Schneider-Stock
Journal:  Cancer Lett       Date:  2008-11-21       Impact factor: 8.679

7.  Expression of DNA repair proteins MSH2, MLH1 and MGMT in human benign and malignant thyroid lesions: an immunohistochemical study.

Authors:  Constantinos Giaginis; Christina Michailidi; Vasileios Stolakis; Paraskevi Alexandrou; Gerasimos Tsourouflis; Jerzy Klijanienko; Ioanna Delladetsima; Stamatios Theocharis
Journal:  Med Sci Monit       Date:  2011-02-25

8.  MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities.

Authors:  Emmanuelle Crinière; Gentian Kaloshi; Florence Laigle-Donadey; Julie Lejeune; Nathalie Auger; Alexandra Benouaich-Amiel; Sibille Everhard; Karima Mokhtari; Marc Polivka; Jean-Yves Delattre; Khê Hoang-Xuan; Joëlle Thillet; Marc Sanson
Journal:  J Neurooncol       Date:  2007-01-12       Impact factor: 4.506

9.  Expression of DNA-repair proteins and their significance in pancreatic cancer and non-cancerous pancreatic tissues of Sprague-Dawley rats.

Authors:  Xing-guo Tan; Zhu-lin Yang; Le-ping Yang; Xiong-ying Miao
Journal:  World J Surg Oncol       Date:  2014-02-06       Impact factor: 2.754

10.  Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer.

Authors:  Meng Li; Curt Balch; John S Montgomery; Mikyoung Jeong; Jae Hoon Chung; Pearlly Yan; Tim H M Huang; Sun Kim; Kenneth P Nephew
Journal:  BMC Med Genomics       Date:  2009-06-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.